CVKD - Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

822 A1A North
Suite 306
Ponte Vedra, FL 32082
United States
904 300 0701
https://www.cadrenal.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Quang X. Pham	Chairman & CEO	822.17k	N/A	1965
Mr. Matthew K. Szot CPA, CPA	Co-Founder & CFO	359.61k	N/A	1974
Dr. Douglas W. Losordo FACC, FAHA, M.D.	Chief Medical Officer	23.36k	N/A	1958

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Corporate governance

Cadrenal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.